Aligos Therapeutics(ALGS.US)

Last Updated 19:00:00 ET
longbridge loading

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 | ALGS Stock News

StockTitan·
US
ALGS
-3.36%
US
LABU
-2.35%
US
IHE
+1.26%
StockTitan·
US
ALGS
-3.36%
US
LABU
-2.35%
US
IHE
+1.26%

Aligos Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 2.83 M

Earnings Watch·
US
ALGS
-3.36%
Earnings Watch·
US
ALGS
-3.36%

Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright

Tip Ranks·
US
ALGS
-3.36%
US
BIB
+0.05%
US
LABU
-2.35%
Tip Ranks·
US
ALGS
-3.36%
US
BIB
+0.05%
US
LABU
-2.35%

10 Health Care Stocks Moving In Friday's Intraday Session

benzinga_article·
US
ENVB
-1.86%
US
ALGS
-3.36%
US
PBM
-15.18%
benzinga_article·
US
ENVB
-1.86%
US
ALGS
-3.36%
US
PBM
-15.18%

Aligos and Xiamen Amoytop sign deal for HBV therapy

Pharmaceutical Technology·
US
ALGS
-3.36%
US
IHE
+1.26%
US
ARKG
+0.04%
Pharmaceutical Technology·
US
ALGS
-3.36%
US
IHE
+1.26%
US
ARKG
+0.04%

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

benzinga_article·
US
ALGS
-3.36%
benzinga_article·
US
ALGS
-3.36%

Aligos Therapeutics shares are trading higher after the company announced that it has entered into an exclusive license agreement to develop and commercialize pevifoscorvir sodium with Xiamen Amoytop Biotech

benzinga_article·
US
ALGS
-3.36%
US
IBBQ
+0.07%
US
BIB
+0.05%
benzinga_article·
US
ALGS
-3.36%
US
IBBQ
+0.07%
US
BIB
+0.05%
© 2026 Longbridge｜Disclaimer